Chikungunya virus vaccine - Themis Bioscience

Drug Profile

Chikungunya virus vaccine - Themis Bioscience

Alternative Names: Measles-vectored Chikungunya vaccine; MV-CHIK

Latest Information Update: 02 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Themis Bioscience
  • Developer National Institute of Allergy and Infectious Diseases; Themis Bioscience
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chikungunya virus infections

Most Recent Events

  • 24 Aug 2018 Themis Bioscience plans a phase II trial for Chikungunya Virus Infection (Prevention) in United Kingdom (NCT03635086)
  • 13 Jun 2018 Chikungunya virus vaccine - Themis Bioscience receives Priority Medicine (PRIME) status for Chikungunya virus infections (Prevention) in European Union
  • 13 Jun 2018 Themis Bioscience plans a phase III trial for Chikungunya virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top